In particular, one patient with KRAS and NRAS wild-type who initially responded to chemotherapy plus cetuximab but that successively progressed, evidenced a K57 T MEK1 mutation in the NGS analysis of the primary tumour and liver metastasis [16]. The gene discussed is KRAS; the disease is neoplasm.